iOmx Therapeutics appoints Dr. Christine Rothe as new Chief Development Officer 

Martinsried / Munich, Germany, 23 February 2023 - iOmx Therapeutics AG, a biopharmaceutical company developing cancer therapeutics based on next generation immune checkpoint targets, today announced the appointment of Dr. Christine Rothe as Chief Development Officer. Dr. Rothe brings over 25 years of biopharma industry experience in research and drug discovery in various disease areas.

“I am delighted to have Christine join the iOmx team and lead our drug discovery and development activities. Her excellent track record in R&D and wealth of experience in immuno-oncology and biologics development will be particularly valuable as we further evolve our pipeline,” said Dr. Apollon Papadimitriou, CEO of iOmx Therapeutics. “Besides our most advanced drug candidate, OMX-0407, a first-in-class oral SIK3 inhibitor ready for clinic, we are rapidly advancing our portfolio of novel checkpoint inhibitors towards clinical development.”

“With its powerful screening platform iOTarg^TM, iOmx is well positioned to successfully identify novel immune checkpoint targets that are key for the development of next-generation cancer immunotherapy drugs addressing current gaps in cancer therapy,” said Dr. Christine Rothe, CDO of iOmx Therapeutics. “I am honored to join the iOmx team on its journey to deliver innovative drugs that will transform the lives of cancer patients in need. I look forward to adding scientific knowledge and leadership experience to complement and further strengthen iOmx’ R&D capacity.”

Dr. Christine Rothe joins iOmx Therapeutics from Pieris Pharmaceuticals, where she served as VP Early-Stage Project Leadership & Data Science. Prior to this, she was VP Discovery & Alliance Management with Pieris. She played a major role in shaping the drug discovery process and in advancing novel therapeutics in immuno-oncology and other disease areas from program inception towards the clinic. Dr. Rothe began her industry career at MorphoSys, holding several positions in R&D and Alliance Management. In these positions, she led technology development and therapeutic antibody project teams. She received her Ph.D. in cell biology from the University of Regensburg.

About iOmx Therapeutics
iOmx Therapeutics () is a biopharmaceutical company focused on developing first-in-class cancer immuno-therapeutics addressing novel immune checkpoints hijacked by cancer cells. Utilizing its iOTarg™ high-throughput screening platform, iOmx has identified a number of proprietary tumor-associated next-generation immune checkpoints and is advancing a preclinical stage pipeline of promising drug candidates that have the potential to address cancers that are resistant to current immunotherapies. The company’s lead program IMT-07 targets SIK3, an immune protective kinase in multiple solid tumors. Founded in 2016 based on the work of its scientific founders Philipp Beckhove, MD, and Nisit Khandelwal, Ph.D., conducted at the German Cancer Research Center, iOmx is backed by international venture capital investors, such as Wellington Partners, Sofinnova Partners and M Ventures as well as MIG Capital and Athos Biopharma. iOmx is based in Martinsried/Munich, Germany.

Contact
MC Services AG
Katja Arnold, Julia von Hummel, Shaun Brown
T: +49(0)89 2102280